Tarek M. Mekhail, MD

Medical Director (Thoracic Cancer), Medical Oncologist

Cancer Research

Expertise of Tarek M. Mekhail, MD

Biography: Dr. Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd is board-certified in internal medicine, hematology and oncology. Dr. Mekhail serves as medical director of the Thoracic Cancer Program at the Florida Hospital Cancer Institute. He joined the team from the Cleveland Clinic where he was the director of the Lung Cancer Medical Oncology Program. Dr. Mekhail completed his medical degree at Cairo University in 1988, then went on to complete his medical training in the United Kingdom, where he earned fellowships of the Royal College of Surgeon of Edinburgh and Ireland. He completed his medical oncology fellowship at the Cleveland Clinic in Cleveland, Ohio. He is an associate professor at the University of Central Florida. Dr. Mekhail's extensive experience in the field of lung cancer is bolstered by his many awards, including being voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010.
Education: Cairo University Egypt
Residency: Cleveland Clinic Foundation Ohio
Fellowship: Cleveland Clinic Foundation Ohio
Specialty: Medical Oncology
Board Certifications: American Board of Internal Medicine

Publications

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial

2024, JOURNAL OF THORACIC ONCOLOGY

View publication for "Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial"
Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity

2024, ORAL ONCOLOGY

View publication for "Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity"
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort

2023, JOURNAL OF CLINICAL MEDICINE

View publication for "Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort"

More sources loaded
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

2022, EXPERT REVIEW OF ANTICANCER THERAPY

View publication for "Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer"
GEMSTONE-302: "If you keep doing the same thing you get the same result

2022, CHINESE CLINICAL ONCOLOGY

View publication for "GEMSTONE-302: "If you keep doing the same thing you get the same result"
Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is it an Indolent Phenomenon or a More Ominous Pathologic Process?

2022, AMERICAN JOURNAL OF SURGICAL PATHOLOGY

View publication for "Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma Is it an Indolent Phenomenon or a More Ominous Pathologic Process?"
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors

2022, JOURNAL OF IMMUNOTHERAPY

View publication for "A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors"
Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)

2022, ANNALS OF ONCOLOGY

View publication for "Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)"
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

2022, JTO CLINICAL AND RESEARCH REPORTS

View publication for "Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC"
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

2022, NATURE MEDICINE

View publication for "Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial"

More Publication Information

Associated Clinical Trials for Tarek M. Mekhail, MD

NCT06008093

D419ML00003: A Phase IIIb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum Based Chemotherapy for First Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients who have Mutations or Co mutations in STK11, KEAP1, or KRAS (TRITON)

This study is currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

To assess the efficacy of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in terms of OS, in participants with non-squamous histology who have metastatic...
NCT06064877

AV-299-23-301: A Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma

This study is currently enrolling.

Associated Conditions: Thoracic

Research Area: Cancer Research

Research Location: Orlando, Florida

The main purpose of this study is to investigate the safety, effectiveness, and tolerability (whether side effects can be handled by a participant) of ficlatuzumab at two different doses when given...
NCT04083599

GCT1042-01: A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors

This study is currently enrolling.

Associated Conditions: Malignant Pleural Mesothelioma

Research Area: Cancer Research

Research Location: Orlando, Florida

GEN1042 is a bispecific antibody that crosslinks CD40 on antigen-presenting cells with 4-1BB on activated T cells, thereby inducing conditional stimulation of and co-stimulatory activity on both cell...

More clinical trials loaded
NCT05498428

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer

This study is currently enrolling.

Research Area: Cancer Research

Research Location: Orlando, Florida

The investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...
NCT05261399

We are doing this research study to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC). Investigational means that the drug is not approved by any health authority, except for use in research studies like this. Osimertinib is approved by health authorities for treatment of NSCLC. Osimertinib is known to work well initially, but resistance often occurs after several months of treatment.

This study is currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

We are doing this research study to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC). Investigational...
NCT05364073

FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations

This study is currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Cancer Research

The purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with...
NCT05211895

D9075C00001: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent Chemoradiation Therapy (PACIFIC 8)

This study is currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Cancer Research

Research Location: Orlando, Florida

This study is being carried out in stage III NSCLC which cannot be removed by surgery. In this study, we will identify the effectiveness and safety of a possible treatment combination – durvalumab...
NCT02367781

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer

This study is not currently enrolling.

Associated Conditions: Lung Cancer

Research Area: Cancer Research

[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you...